On 16 June 2020, ResApp signed a two-year, non-exclusive commercial software licensing agreement with Phenix Health Pty Ltd, Australia based virtual super clinic, to use ResApp’s acute respiratory diagnostic test, ResAppDx-EU, in Phenix’s telehealth smartphone app. For the full article you can visit: https://kalkinemedia.com/au/covid-19/government-urged-to-continue-mbs-funded-telehealth-services-resmed-resapp-to-reap-the-benefits
ResApp Health Sign Software Licensing Agreement with Phenix Health On 16 June 2020, ResApp and Phenix Health signed a licensing deal for employing ResAppDx-EU in telehealth smartphone application of Phenix. This agreement is a non-exclusive commercial software licensing agreement for two years. With this deal, ResAppDx-EU can be applied in the telehealth smartphone applications by...
ASX listed digital health company ResApp has signed a memorandum of understanding with health products manufacturer RB, formerly known as Reckitt Benckiser, to develop a smartphone app for consumers that uses ResApp’s cough-based algorithms to identify different respiratory conditions. For the full article please visit:
Cough monitor Resapp (ASX:RAP) has done a deal with telehealth company Phenix Health, following a similar deal by Respiri (ASX:RSH) in April. The software licensing agreement for its ResAppDX-EU cough diagnostic test was first announced in March with a price of $5-10 per test. CEO Tony Keating is expecting first commercial revenues in the coming months through the agreements...
The average GP consultation take about six minutes. That figure is very significant in the context of the two-year, non-exclusive commercial software licensing agreement Resapp Health [ASX:RAP] has just signed with Phenix Health Pty Ltd. Phenix Health Pty Ltd is an integrative medical tech company founded in 2015 as a spin-off from its Australia-wide after-hours...
In March, ResApp announced to have completed the initial integration of ResAppDx-EU into Coviu’s telehealth platform and that ResApp and Coviu had agreed upon a per test fee (range of $ 5-10 per test) for the use of ResAppDx-EU. Meanwhile, ResApp also executed Joint Development Agreement with Phenix Health for integration of ResAppDx-EU into Phenix’s Australian telehealth...
* RESPIRI LTD – ANNOUNCES SIGNING OF A JOINT DEVELOPMENT AGREEMENT (JDA) WITH PHENIX HEALTH PTY LTD * RESPIRI-UNDER DEAL,WHEEZO EHEALTH SAAS MONITORING PLATFORM INTEGRATED INTO PHENIX PROPRIETARY TELEHEALTH PLATFORM, PATIENT DASHBOARDS & ASTHMA PLANS https://au.investing.com/news/stock-market-news/briefrespiri-announces-signing-of-a-joint-development-agreement-with-phenix-health-2092571
ASX-listed ResApp Health will partner with Brisbase-headquartered telehealth provider Phenix Health to integrate ResApp’s acute respiratory diagnostic test into Phenix’s telehealth app. ResApp has recently completed a similar integration of ResAppDx-EU into Coviu’s telehealth platform and is expecting to have it available for use in a few months. The company is also about to launch a consumer-focused...
Press Release Brisbane, Australia, 24 March 2020 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, and Phenix Health Pty Ltd, mobile clinic software developers and providers of an online virtual clinic, have entered into a joint development agreement (JDA) to integrate ResApp’s acute...
Phenix Health delivers online health services 24/7 provided by Australian doctors and healthcare professionals.